Comparison of different serological assays for SARS-CoV-2 in real life.
Identifieur interne : 001288 ( Main/Exploration ); précédent : 001287; suivant : 001289Comparison of different serological assays for SARS-CoV-2 in real life.
Auteurs : Etienne Brochot [France] ; Baptiste Demey [France] ; Lynda Handala [France] ; Catherine François [France] ; Gilles Duverlie [France] ; Sandrine Castelain [France]Source :
- Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology [ 1873-5967 ] ; 2020.
Abstract
BACKGROUND
The emergence of the global SARS-CoV-2 pandemic required the rapid and large-scale deployment of PCR and serological tests in different formats.
OBJECTIVES
Real-life evaluation of these tests is needed. Using 168 samples from patients hospitalized for COVID-19, non-hospitalized patients but infected with SARS-CoV-2, patients participating in screening campaigns, and samples from patients with a history of other seasonal coronavirus infections, we evaluated the clinical performance of 5 serological assays widely used worldwide (WANTAI®, BIORAD®, EUROIMMUN®, ABBOTT® and LIAISON®).
RESULTS
For hospitalized patients, all these assays showed a sensitivity of 100 % from day 9 after the symptoms onset. On the other hand, sensitivity was much lower for patients who did not require hospitalization for COVID-19 confirmed by PCR (from 91.6 % for WANTAI® to 69 % for LIAISON®). These differences do not seem to be due to the antigens chosen by the manufacturers but more to the test formats (IgG detection versus total antibodies). In addition, more than 50 days after a positive PCR for CoV-2-SARS the proportion of positive patients seem to decrease. We did not observe any significant cross-reactions for these techniques with the four other seasonal coronaviruses.
CONCLUSION
In conclusion, the evaluation and knowledge of the serological tests used is important and should require an optimized strategy adaptation of the analysis laboratories to best meet patient's expectations in the face of this health crisis.
DOI: 10.1016/j.jcv.2020.104569
PubMed: 32769023
PubMed Central: PMC7396207
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Comparison of different serological assays for SARS-CoV-2 in real life.</title><author><name sortKey="Brochot, Etienne" sort="Brochot, Etienne" uniqKey="Brochot E" first="Etienne" last="Brochot">Etienne Brochot</name><affiliation wicri:level="1"><nlm:affiliation>Department of Virology, Amiens University Medical Center, Amiens, France; Agents infectieux résistance et chimiothérapie Research Unit, UR4294, Jules Verne University of Picardie, France. Electronic address: etienne.brochot@u-picardie.fr.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Department of Virology, Amiens University Medical Center, Amiens, France; Agents infectieux résistance et chimiothérapie Research Unit, UR4294, Jules Verne University of Picardie</wicri:regionArea><wicri:noRegion>Jules Verne University of Picardie</wicri:noRegion><wicri:noRegion>Jules Verne University of Picardie</wicri:noRegion></affiliation></author><author><name sortKey="Demey, Baptiste" sort="Demey, Baptiste" uniqKey="Demey B" first="Baptiste" last="Demey">Baptiste Demey</name><affiliation wicri:level="1"><nlm:affiliation>Department of Virology, Amiens University Medical Center, Amiens, France; Agents infectieux résistance et chimiothérapie Research Unit, UR4294, Jules Verne University of Picardie, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Department of Virology, Amiens University Medical Center, Amiens, France; Agents infectieux résistance et chimiothérapie Research Unit, UR4294, Jules Verne University of Picardie</wicri:regionArea><wicri:noRegion>Jules Verne University of Picardie</wicri:noRegion><wicri:noRegion>Jules Verne University of Picardie</wicri:noRegion></affiliation></author><author><name sortKey="Handala, Lynda" sort="Handala, Lynda" uniqKey="Handala L" first="Lynda" last="Handala">Lynda Handala</name><affiliation wicri:level="1"><nlm:affiliation>Department of Virology, Amiens University Medical Center, Amiens, France; Agents infectieux résistance et chimiothérapie Research Unit, UR4294, Jules Verne University of Picardie, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Department of Virology, Amiens University Medical Center, Amiens, France; Agents infectieux résistance et chimiothérapie Research Unit, UR4294, Jules Verne University of Picardie</wicri:regionArea><wicri:noRegion>Jules Verne University of Picardie</wicri:noRegion><wicri:noRegion>Jules Verne University of Picardie</wicri:noRegion></affiliation></author><author><name sortKey="Francois, Catherine" sort="Francois, Catherine" uniqKey="Francois C" first="Catherine" last="François">Catherine François</name><affiliation wicri:level="1"><nlm:affiliation>Department of Virology, Amiens University Medical Center, Amiens, France; Agents infectieux résistance et chimiothérapie Research Unit, UR4294, Jules Verne University of Picardie, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Department of Virology, Amiens University Medical Center, Amiens, France; Agents infectieux résistance et chimiothérapie Research Unit, UR4294, Jules Verne University of Picardie</wicri:regionArea><wicri:noRegion>Jules Verne University of Picardie</wicri:noRegion><wicri:noRegion>Jules Verne University of Picardie</wicri:noRegion></affiliation></author><author><name sortKey="Duverlie, Gilles" sort="Duverlie, Gilles" uniqKey="Duverlie G" first="Gilles" last="Duverlie">Gilles Duverlie</name><affiliation wicri:level="1"><nlm:affiliation>Department of Virology, Amiens University Medical Center, Amiens, France; Agents infectieux résistance et chimiothérapie Research Unit, UR4294, Jules Verne University of Picardie, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Department of Virology, Amiens University Medical Center, Amiens, France; Agents infectieux résistance et chimiothérapie Research Unit, UR4294, Jules Verne University of Picardie</wicri:regionArea><wicri:noRegion>Jules Verne University of Picardie</wicri:noRegion><wicri:noRegion>Jules Verne University of Picardie</wicri:noRegion></affiliation></author><author><name sortKey="Castelain, Sandrine" sort="Castelain, Sandrine" uniqKey="Castelain S" first="Sandrine" last="Castelain">Sandrine Castelain</name><affiliation wicri:level="1"><nlm:affiliation>Department of Virology, Amiens University Medical Center, Amiens, France; Agents infectieux résistance et chimiothérapie Research Unit, UR4294, Jules Verne University of Picardie, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Department of Virology, Amiens University Medical Center, Amiens, France; Agents infectieux résistance et chimiothérapie Research Unit, UR4294, Jules Verne University of Picardie</wicri:regionArea><wicri:noRegion>Jules Verne University of Picardie</wicri:noRegion><wicri:noRegion>Jules Verne University of Picardie</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2020">2020</date><idno type="RBID">pubmed:32769023</idno><idno type="pmid">32769023</idno><idno type="doi">10.1016/j.jcv.2020.104569</idno><idno type="pmc">PMC7396207</idno><idno type="wicri:Area/Main/Corpus">000676</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000676</idno><idno type="wicri:Area/Main/Curation">000676</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000676</idno><idno type="wicri:Area/Main/Exploration">000676</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Comparison of different serological assays for SARS-CoV-2 in real life.</title><author><name sortKey="Brochot, Etienne" sort="Brochot, Etienne" uniqKey="Brochot E" first="Etienne" last="Brochot">Etienne Brochot</name><affiliation wicri:level="1"><nlm:affiliation>Department of Virology, Amiens University Medical Center, Amiens, France; Agents infectieux résistance et chimiothérapie Research Unit, UR4294, Jules Verne University of Picardie, France. Electronic address: etienne.brochot@u-picardie.fr.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Department of Virology, Amiens University Medical Center, Amiens, France; Agents infectieux résistance et chimiothérapie Research Unit, UR4294, Jules Verne University of Picardie</wicri:regionArea><wicri:noRegion>Jules Verne University of Picardie</wicri:noRegion><wicri:noRegion>Jules Verne University of Picardie</wicri:noRegion></affiliation></author><author><name sortKey="Demey, Baptiste" sort="Demey, Baptiste" uniqKey="Demey B" first="Baptiste" last="Demey">Baptiste Demey</name><affiliation wicri:level="1"><nlm:affiliation>Department of Virology, Amiens University Medical Center, Amiens, France; Agents infectieux résistance et chimiothérapie Research Unit, UR4294, Jules Verne University of Picardie, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Department of Virology, Amiens University Medical Center, Amiens, France; Agents infectieux résistance et chimiothérapie Research Unit, UR4294, Jules Verne University of Picardie</wicri:regionArea><wicri:noRegion>Jules Verne University of Picardie</wicri:noRegion><wicri:noRegion>Jules Verne University of Picardie</wicri:noRegion></affiliation></author><author><name sortKey="Handala, Lynda" sort="Handala, Lynda" uniqKey="Handala L" first="Lynda" last="Handala">Lynda Handala</name><affiliation wicri:level="1"><nlm:affiliation>Department of Virology, Amiens University Medical Center, Amiens, France; Agents infectieux résistance et chimiothérapie Research Unit, UR4294, Jules Verne University of Picardie, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Department of Virology, Amiens University Medical Center, Amiens, France; Agents infectieux résistance et chimiothérapie Research Unit, UR4294, Jules Verne University of Picardie</wicri:regionArea><wicri:noRegion>Jules Verne University of Picardie</wicri:noRegion><wicri:noRegion>Jules Verne University of Picardie</wicri:noRegion></affiliation></author><author><name sortKey="Francois, Catherine" sort="Francois, Catherine" uniqKey="Francois C" first="Catherine" last="François">Catherine François</name><affiliation wicri:level="1"><nlm:affiliation>Department of Virology, Amiens University Medical Center, Amiens, France; Agents infectieux résistance et chimiothérapie Research Unit, UR4294, Jules Verne University of Picardie, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Department of Virology, Amiens University Medical Center, Amiens, France; Agents infectieux résistance et chimiothérapie Research Unit, UR4294, Jules Verne University of Picardie</wicri:regionArea><wicri:noRegion>Jules Verne University of Picardie</wicri:noRegion><wicri:noRegion>Jules Verne University of Picardie</wicri:noRegion></affiliation></author><author><name sortKey="Duverlie, Gilles" sort="Duverlie, Gilles" uniqKey="Duverlie G" first="Gilles" last="Duverlie">Gilles Duverlie</name><affiliation wicri:level="1"><nlm:affiliation>Department of Virology, Amiens University Medical Center, Amiens, France; Agents infectieux résistance et chimiothérapie Research Unit, UR4294, Jules Verne University of Picardie, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Department of Virology, Amiens University Medical Center, Amiens, France; Agents infectieux résistance et chimiothérapie Research Unit, UR4294, Jules Verne University of Picardie</wicri:regionArea><wicri:noRegion>Jules Verne University of Picardie</wicri:noRegion><wicri:noRegion>Jules Verne University of Picardie</wicri:noRegion></affiliation></author><author><name sortKey="Castelain, Sandrine" sort="Castelain, Sandrine" uniqKey="Castelain S" first="Sandrine" last="Castelain">Sandrine Castelain</name><affiliation wicri:level="1"><nlm:affiliation>Department of Virology, Amiens University Medical Center, Amiens, France; Agents infectieux résistance et chimiothérapie Research Unit, UR4294, Jules Verne University of Picardie, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Department of Virology, Amiens University Medical Center, Amiens, France; Agents infectieux résistance et chimiothérapie Research Unit, UR4294, Jules Verne University of Picardie</wicri:regionArea><wicri:noRegion>Jules Verne University of Picardie</wicri:noRegion><wicri:noRegion>Jules Verne University of Picardie</wicri:noRegion></affiliation></author></analytic><series><title level="j">Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology</title><idno type="eISSN">1873-5967</idno><imprint><date when="2020" type="published">2020</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><p><b>BACKGROUND</b></p><p>The emergence of the global SARS-CoV-2 pandemic required the rapid and large-scale deployment of PCR and serological tests in different formats.</p></div><div type="abstract" xml:lang="en"><p><b>OBJECTIVES</b></p><p>Real-life evaluation of these tests is needed. Using 168 samples from patients hospitalized for COVID-19, non-hospitalized patients but infected with SARS-CoV-2, patients participating in screening campaigns, and samples from patients with a history of other seasonal coronavirus infections, we evaluated the clinical performance of 5 serological assays widely used worldwide (WANTAI®, BIORAD®, EUROIMMUN®, ABBOTT® and LIAISON®).</p></div><div type="abstract" xml:lang="en"><p><b>RESULTS</b></p><p>For hospitalized patients, all these assays showed a sensitivity of 100 % from day 9 after the symptoms onset. On the other hand, sensitivity was much lower for patients who did not require hospitalization for COVID-19 confirmed by PCR (from 91.6 % for WANTAI® to 69 % for LIAISON®). These differences do not seem to be due to the antigens chosen by the manufacturers but more to the test formats (IgG detection versus total antibodies). In addition, more than 50 days after a positive PCR for CoV-2-SARS the proportion of positive patients seem to decrease. We did not observe any significant cross-reactions for these techniques with the four other seasonal coronaviruses.</p></div><div type="abstract" xml:lang="en"><p><b>CONCLUSION</b></p><p>In conclusion, the evaluation and knowledge of the serological tests used is important and should require an optimized strategy adaptation of the analysis laboratories to best meet patient's expectations in the face of this health crisis.</p></div></front></TEI><pubmed><MedlineCitation Status="In-Process" Owner="NLM"><PMID Version="1">32769023</PMID><DateRevised><Year>2020</Year><Month>09</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1873-5967</ISSN><JournalIssue CitedMedium="Internet"><Volume>130</Volume><PubDate><Year>2020</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology</Title><ISOAbbreviation>J. Clin. Virol.</ISOAbbreviation></Journal><ArticleTitle>Comparison of different serological assays for SARS-CoV-2 in real life.</ArticleTitle><Pagination><MedlinePgn>104569</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">S1386-6532(20)30311-5</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jcv.2020.104569</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The emergence of the global SARS-CoV-2 pandemic required the rapid and large-scale deployment of PCR and serological tests in different formats.</AbstractText><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">Real-life evaluation of these tests is needed. Using 168 samples from patients hospitalized for COVID-19, non-hospitalized patients but infected with SARS-CoV-2, patients participating in screening campaigns, and samples from patients with a history of other seasonal coronavirus infections, we evaluated the clinical performance of 5 serological assays widely used worldwide (WANTAI®, BIORAD®, EUROIMMUN®, ABBOTT® and LIAISON®).</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">For hospitalized patients, all these assays showed a sensitivity of 100 % from day 9 after the symptoms onset. On the other hand, sensitivity was much lower for patients who did not require hospitalization for COVID-19 confirmed by PCR (from 91.6 % for WANTAI® to 69 % for LIAISON®). These differences do not seem to be due to the antigens chosen by the manufacturers but more to the test formats (IgG detection versus total antibodies). In addition, more than 50 days after a positive PCR for CoV-2-SARS the proportion of positive patients seem to decrease. We did not observe any significant cross-reactions for these techniques with the four other seasonal coronaviruses.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">In conclusion, the evaluation and knowledge of the serological tests used is important and should require an optimized strategy adaptation of the analysis laboratories to best meet patient's expectations in the face of this health crisis.</AbstractText><CopyrightInformation>Copyright © 2020 Elsevier B.V. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Brochot</LastName><ForeName>Etienne</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Virology, Amiens University Medical Center, Amiens, France; Agents infectieux résistance et chimiothérapie Research Unit, UR4294, Jules Verne University of Picardie, France. Electronic address: etienne.brochot@u-picardie.fr.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Demey</LastName><ForeName>Baptiste</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Virology, Amiens University Medical Center, Amiens, France; Agents infectieux résistance et chimiothérapie Research Unit, UR4294, Jules Verne University of Picardie, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Handala</LastName><ForeName>Lynda</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Virology, Amiens University Medical Center, Amiens, France; Agents infectieux résistance et chimiothérapie Research Unit, UR4294, Jules Verne University of Picardie, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>François</LastName><ForeName>Catherine</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Virology, Amiens University Medical Center, Amiens, France; Agents infectieux résistance et chimiothérapie Research Unit, UR4294, Jules Verne University of Picardie, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Duverlie</LastName><ForeName>Gilles</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Virology, Amiens University Medical Center, Amiens, France; Agents infectieux résistance et chimiothérapie Research Unit, UR4294, Jules Verne University of Picardie, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Castelain</LastName><ForeName>Sandrine</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Virology, Amiens University Medical Center, Amiens, France; Agents infectieux résistance et chimiothérapie Research Unit, UR4294, Jules Verne University of Picardie, France.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>08</Month><Day>02</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Clin Virol</MedlineTA><NlmUniqueID>9815671</NlmUniqueID><ISSNLinking>1386-6532</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Performance assays</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">Serological assays</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>07</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>07</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>8</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>8</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>8</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32769023</ArticleId><ArticleId IdType="pii">S1386-6532(20)30311-5</ArticleId><ArticleId IdType="doi">10.1016/j.jcv.2020.104569</ArticleId><ArticleId IdType="pmc">PMC7396207</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>France</li></country></list><tree><country name="France"><noRegion><name sortKey="Brochot, Etienne" sort="Brochot, Etienne" uniqKey="Brochot E" first="Etienne" last="Brochot">Etienne Brochot</name></noRegion><name sortKey="Castelain, Sandrine" sort="Castelain, Sandrine" uniqKey="Castelain S" first="Sandrine" last="Castelain">Sandrine Castelain</name><name sortKey="Demey, Baptiste" sort="Demey, Baptiste" uniqKey="Demey B" first="Baptiste" last="Demey">Baptiste Demey</name><name sortKey="Duverlie, Gilles" sort="Duverlie, Gilles" uniqKey="Duverlie G" first="Gilles" last="Duverlie">Gilles Duverlie</name><name sortKey="Francois, Catherine" sort="Francois, Catherine" uniqKey="Francois C" first="Catherine" last="François">Catherine François</name><name sortKey="Handala, Lynda" sort="Handala, Lynda" uniqKey="Handala L" first="Lynda" last="Handala">Lynda Handala</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidFranceV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001288 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001288 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= CovidFranceV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:32769023
|texte= Comparison of different serological assays for SARS-CoV-2 in real life.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:32769023" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a CovidFranceV1
| This area was generated with Dilib version V0.6.37. |  |